Healthcare Industry News: Pegasus
News Release - October 16, 2006
Pegasus Biologics Enters Wound Care Market With FDA Clearance for DermADAPT(TM) BiomatrixIRVINE, Calif.--(HSMN NewsFeed)--Pegasus Biologics, Inc., developers of advanced biologic scaffolds, announced today that they have received FDA clearance for the DermADAPT(TM) Biomatrix Wound Dressing, a highly organized collagen matrix intended for the local management of moderate to heavy exuding wounds. The Company will initially focus on the enormous opportunity within the diabetic foot ulcer market.
"The ability to market the DermADAPT Biomatrix for wound care is another incredible opportunity for Pegasus Biologics," stated President and Founder, France Dixon Helfer. "In the US alone, five million diabetic patients suffer from debilitating, often recurrent foot ulcers. The DermADAPT Biomatrix offers a new solution that provides hope to patients who otherwise may require amputation. Our enormous success with the acceptance of our OrthADAPT(TM) Bioimplant in the orthopedic, sports medicine and podiatry field, will allow us to segue into the extremities and wound care markets. Many of the same physicians who have embraced our OrthADAPT Bioimplant for ligament and tendon repairs will adopt the DermADAPT for management of diabetic foot wounds." The clearance received allows the Company to market the DermADAPT Biomatrix for the management of a variety of wounds including pressure ulcers, venous ulcers, surgical, podiatric, and trauma wounds including partial thickness burns.
Al Weinstein, Executive VP, Sales and Marketing added, "We are grateful for the acceptance we have had of the OrthADAPT Bioimplant clinically, and we believe physicians will be extremely pleased with advantages offered by the DermADAPT Biomatrix. Unlike some other collagen-based wound dressings, it is strong and stable, maintaining an ideal environment for wound healing. At the same time, it is thin and pliable, and conforms well to the wound bed."
The DermADAPT Biomatrix and the OrthADAPT Bioimplants utilize Pegasus Biologics' proprietary licensed technologies, UltiFIX® and UltiSTER(TM), that stabilize and sterilize biological tissues using safe and nondestructive methods, resulting in decellularized collagen matrices that are extremely biocompatible and strong. Studies have indicated that Pegasus biologic scaffolds are resistant to enzymes for controlled biodegradation and subsequent remodeling in the patient.
Pegasus Biologics, Inc.
Pegasus Biologics, Inc. (Irvine, CA) is a privately held company focused on the development and commercialization of next generation biologics utilizing the Company's unique and patented technologies. Additional information on the Company can be found at www.Pegasusbio.com.
Source: Pegasus Biologics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.